← Back to headlines
Context Therapeutics Stock Rises on FDA Fast Track Status
Context Therapeutics saw its stock rise after its lead asset was granted fast track status by the FDA.
2 Apr, 15:27 — 2 Apr, 15:27
Sources
Showing 1 of 1 sources
Related Stories
Iloilo Reinstates Health Protocols Amid Extreme Heat
just now
Four arrested for selling P102 million in fake anti-cancer medicines in Makati
just now
Vigilance Urged After Death of Two Children in Abandoned Car
just now
Long Waiting Lists for Pediatric Eye Doctors in Latvia Lead to Unborn Child Registrations
just now